65579-92-2

Upstream product

• 75-36-5 acetyl chloride 
• 613-45-6 2,4-Dimethoxybenzaldehyde 

Downstream Products

• 117690-96-7 4-(4-cyanobutoxy)-5-formyl-2-hydroxyacetophenone 
• 117705-66-5 5-(hydroxymethyl)-2,4-dihydroxyacetophenone 
• 117705-81-4 4-<(6-cyanohexyl)oxy>-5-<(methylthio)methyl>-2-hydroxyacetophenone 
• 117705-82-5 4-<(6-cyanohexyl)oxy>-5-(methoxymethyl)-2-hydroxyacetophenone 
• 117690-74-1 4-<(6-cyanohexyl)oxy>-5-(hydroxymethyl)-2-hydroxyacetophenone 
• 117705-80-3 4-<(6-cyanohexyl)oxy>-5-(chloromethyl)-2-hydroxyacetophenone 

Relevant academic research and scientific papers

Leukotriene B4 Receptor Antagonists: The LY255283 Series of Hydroxyacetophenones

A series of hydroxyacetophenones was prepared for evaluation as leukotriene B4 (LTB4) receptor antagonists, culminating in 1-oxy>phenyl>ethanone (compound 35, LY255283).Using an assay for inhibition of specific LTB4 binding to human PMN, we found that substitution of a nonpolar substituent in the 5-position was required for activity.Best activity was realized with hydrogen in the 3-position, hydroxyl in the 2-position, short chain alkyl ketone in the 1-position, and a six- or eight-carbon chain linking the oxygen in the 4-position with an unsaturated terminal function.Compound 35, having an IC50 of 87 nM in the binding assay, was chosen for further preclinical evaluation.

ANTI-INFLAMMATORY AGENTS

This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.